Plain English Summary
Background and study aims
It is estimated that depressive disorders (illnesses involving low mood) will become the third most burdensome health problem in the low income countries after HIV/AIDS and childbirth-related conditions. Even though effective treatments for depression are available, previous studies in Nigeria showed that about four out of five people with severe mental disorders, particularly depression, had received no treatment in the previous year. The Nigerian health system, similar to that in most of sub-Saharan Africa, has a shortage of human and material resources. For example, there is less than one psychiatrist to one million population and the few available specialists are concentrated in urban areas. A way to manage this limitation is to integrate mental health into primary health care, where services are mostly provided by non-physician primary health care workers. This strategy is much more likely to be viable and affordable because these resources already exist, are less expensive, and are accessible. However, this strategy also has some limitations. A new model to address the treatment gap for depression must therefore provide a more efficient way of allocating existing resources to give effective treatment. Stepped-care models claim to maximize efficiency by allocating available resources strictly according to needs, offering greater resources to those with complex or severe problems. In this model, non-physician primary care providers deliver the bulk of essential mental health service and receive structured and targeted supervision and support from physicians and more highly trained mental health specialists on the specific needs of the patients. The proposed study aims to compare the effectiveness and cost-effectiveness of this model, in which the supervision and support are provided with the use of mobile phones, with care as usual.
Who can participate?
Participants will be adults, aged 18 years or over, consulting the participating primary health care clinics during the study.
What does the study involve?
Patients will be randomly allocated to one of to two groups: intervention group and control group. Patients in the intervention group will receive manual-driven psychological and antidepressant treatments from primary care providers as well as medical or specialist assessments and care based on the severity of their depression. Patients in the control arm will receive care as usual, enhanced by further training of the providers, in that group, on the nature and management of depression. Recovery from depression will be assessed at 12 months. Changes in cost-effectiveness, disability and quality of life will also be measured.
What are the possible benefits and risks of participating?
Participants in both groups will benefit from improved care of depression. The risk associated with detailed and possible troubling assessment of sensitive emotional issues will be managed by the use of well-trained research staff and the availability of a structured medical response to severe distress that may be experienced by participants.
Where is the study run from?
The study will be run from the primary health care clinics (PHCs) in four selected local government areas in Oyo State, Nigeria. Patient recruitment will be conducted in 20 PHCs drawn from two urban and two rural local government areas.
When is the study starting and how long is it expected to run for?
The study will start in November 2013 and is expected to run until October 2016.
Who is funding the study?
The study is funded jointly by the Medical Research Council (UK), the Wellcome Trust (UK), and the Department for International Development (DFID) (UK).
Who is the main contact?
Professor Oye Gureje
ogureje@comui.edu.ng
Trial website
Contact information
Type
Scientific
Primary contact
Prof Oye Gureje
ORCID ID
Contact details
Department of Psychiatry
University College Hospital
Ibadan
PMB5116
Nigeria
+234 2 815 0258
ogureje@comui.edu.ng
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
UI/EC/10/0041
Study information
Scientific title
A cluster randomized controlled trial of a STEPped-CARE intervention for depression in primary care
Acronym
STEPCARE
Study hypothesis
A stepped-care intervention program for depression delivered mostly by non-physician primary health care workers, in which medical and specialist supervision and support are provided with the use of mobile phones, will be more effective and cost-effective than care as usual at improving clinical outcome and quality of life at 12 months.
Added 12/02/2015:
This is the Main Phase of the project. A Pilot Phase has been conducted in 6 clusters that are not included in the Main Phase. For the pilot, 165 subjects were enrolled to the intervention arm and 69 to the control arm. The objectives of the pilot were:
1. To study the organizational structure of primary care service in regard to the provision of care for persons with depression.
2. To explore the understanding of depression and expectations for its treatment by primary care providers, patients, and their relatives. In particular, to explore views about psychological and pharmacological interventions.
3. To develop an intervention package consisting of problem solving treatment, psychoeducation, and structured support by physicians and psychiatrists, using mobile telephony.
4. To assess the feasibility of and different strategies for recruiting and randomizing of patients for a controlled intervention trial.
5. To assess the fidelity of delivering the intervention by primary care providers.
6. To explore strategies for improved recruitment and retention of subjects.
7. To explore strategies for adequate staff and organizational support for the trial
8. To assess satisfaction with the intervention by patients and staff.
9. To explore the factors associated with patient retention in the study and adherence with the intervention.
Ethics approval
University of Ibadan/University College Hospital Joint Ethics Committee
Study design
Cluster randomized controlled trial
Primary study design
Interventional
Secondary study design
Cluster randomised trial
Trial setting
GP practices
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Depression
Intervention
Patients are randomised to two arms: an intervention arm in which a manualized stepped-care intervention package is provided and a control arm delivering usual care.
The intervention to be provided incorporates components of the World Health Organization mhGAP-Intervention Guide for depression, contextualized and adapted for the Nigerian health system, and Problem Solving Treatment (PST). All individuals consenting into the trial receive STEP 1 consisting of a psychological intervention delivered by the primary health care workers (PHCWs). Those individuals with PHQ-9 ≥ 15 at baseline are immediately assessed (with General Physician (GP) support) for medication. At 8 weeks all patients are assessed again with the PHQ-9 and those not responding or whose symptoms worsen (PHQ-9 ≥11 and/or a decrease of less than 50% on PHQ-9 baseline score) are moved to STEP 2 consisting of an assessment in consultation with a GP with a view of initiating pharmacotherapy. Those who were already on medication but met the same criteria are also assessed with a view to modifying medication regime. STEP 1 or the psychological component consists of psychoeducation, reactivation of social network, and PST. This intervention is delivered in 8-weekly sessions to all people entering the program. The initial session is dedicated to psychoeducation in which the symptoms of depression, possible causes and treatments are discussed. The following 5 sessions contemplate teaching the basics of PST using examples provided in the manual and the person's own examples. Session 6 is dedicated to exploring support through social networks and the last two sessions are about integrating it all and preparing for the future. All sessions are face-to-face in the clinic.
STEP 2 consists of assessment and eventual prescription of antidepressants. The first line will be amitryptiline, which non-physician primary care providers in Nigeria are authorized to prescribe.
If patients do not improve after this step their cases can be discussed with a psychiatrist by the GP in the final STEP 3 in the sequence covering up to 6 months. All the steps, clinical decisions, and actions to be taken are detailed in a manual. All supervision and consultations with doctors will be through mobile phones except when a face-to-face review is deemed necessary and feasible. PHCWs will receive supervision from the GP when PHQ-9 denotes severe depression; there is no improvement at 8 week; and in cases of emergencies (e.g. suicide risk or serious drug reaction). All telephone reviews and consultations will be on as-needed basis, structured, and following a manualized flow-chart that proceeds from the PHCWs through to the GP and to the psychiatrist. The PHCWs will co-ordinate all management procedures. Prior to recruitment of patients, providers in the intervention arm will be offered a training on the recognition of depression, the delivery of the manualized intervention package, as well as procurement and documentation of support and supervision using mobile phones.
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measure
The primary outcome will be the proportion of participants recovering from depression at 12 months from entering the trial (who no longer meets the DSM-V criteria for major depression)
Secondary outcome measures
Secondary outcomes will be conducted at 3, 6 and 9 months and will consist of:
1. PHQ9 scores (in order to address the possibility that even though individuals may have recovered from a major depressive disorder, significant depressive symptoms may still persist
2. Disability as assessed using the WHO Disability Assessment Scale (since there is evidence that disability may follow a different trajectory from that of symptoms among persons with depression)
3. Quality of life as measured by WHO Quality of Life instrument (in view of the evidence that health-related quality of life is a different and important dimension of illness experience other than disability and may more accurately capture personal views of impairment). Service use information, that provides data for computation of cost of care, will be collected using the Service Use Questionnaire.
Overall trial start date
01/11/2013
Overall trial end date
31/10/2016
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Consecutive attendees who consent will be screened while waiting to see primary care providers. Those who screen positive will be assessed for inclusion and exclusion, and if eligible, invited to enter the study. Patients much satisfy all of the following to be considered for study entry:
1. Adults, aged 18 years or over, with a score of 11 or more on the Patient Health Questionnaire (PHQ-9)
2. Confirmed 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-V) diagnosis of depression using the Composite International Diagnostic Interview (CIDI)
3. Provide informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
1800
Total final enrolment
1178
Participant exclusion criteria
1. Immediate need for medical attention
2. Pregnant
3. Actively suicidal
4. Presence of bipolar or psychotic disorder or severe substance dependence
5. Unlikely to be in the neighbourhood in the following 12 months
Recruitment start date
01/12/2013
Recruitment end date
01/08/2015
Locations
Countries of recruitment
Nigeria
Trial participating centre
University College Hospital
Ibadan
PMB5116
Nigeria
Sponsor information
Organisation
University of Ibadan (Nigeria)
Sponsor details
College of Medicine
University College Hospital
PMB 5116
Ibadan
PMB 5116
Nigeria
-
provost@comui.edu.ng
Sponsor type
University/education
Website
Funders
Funder type
Research council
Funder name
Medical Research Council (UK)
Alternative name(s)
MRC
Funding Body Type
government organisation
Funding Body Subtype
National government
Location
United Kingdom
Funder name
Wellcome Trust (UK) (WT ref: 100070)
Alternative name(s)
Funding Body Type
private sector organisation
Funding Body Subtype
International organizations
Location
United Kingdom
Results and Publications
Publication and dissemination plan
We intend to publish the pilot report in September 2015.
Intention to publish date
30/09/2015
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2015 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/26149444
2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25929840
2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31097414 (added 20/05/2019)